Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €31.41 EUR
Change Today +0.57 / 1.84%
Volume 0.0
MYD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYD) Snapshot

Open
€30.81
Previous Close
€30.84
Day High
€31.41
Day Low
€30.63
52 Week High
03/20/15 - €35.08
52 Week Low
06/2/14 - €24.07
Market Cap
2.2B
Average Volume 10 Days
31.6
EPS TTM
--
Shares Outstanding
69.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYRIAD GENETICS INC (MYD)

myriad genetics inc (MYD) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYD) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. The company operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes; diagnose diseases, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

1,649 Employees
Last Reported Date: 08/13/14
Founded in 1991

myriad genetics inc (MYD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $997.0K
President of Myriad Genetic Laboratories
Total Annual Compensation: $568.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $734.0K
Chief Scientific Officer
Total Annual Compensation: $733.6K
Compensation as of Fiscal Year 2014.

myriad genetics inc (MYD) Key Developments

Myriad Genetics Inc. Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2015 and Revises Earnings Guidance for the Full Year 2015

Myriad Genetics Inc. announced unaudited consolidated earnings results for third quarter and nine months ended March 31, 2015. For the quarter, the company reported total revenue of $179,985,000, operating income of $35,740,000, income before income taxes of $35,566,000, net income of $21,475,000 or $0.29 per diluted share, non-GAAP operating income of $46,239,000, non-GAAP net income of $29,261,000 or $0.4 per diluted share, GAAP cash flow from operations of $29,878,000, capital expenditures of $4,457,000 compared to the total revenue of $182,924,000, operating income of $55,287,000, income before income taxes of $57,343,000, net income of $36,770,000 or $0.48 per diluted share, non-GAAP operating income of $69,056,000, non-GAAP net income of $46,202,000 or $0.6 per diluted share, GAAP cash flow from operations of $11,249,000, capital expenditures of $1,555,000 for the same quarter a year ago. For the nine months, the company reported total revenue of $533,216,000, operating income of $98,002,000, income before income taxes of $99,384,000, net income of $61,488,000 or $0.82 per diluted share, non-GAAP operating income of $119,084,000, non-GAAP net income of $78,155,000 or $1.04 per diluted share, GAAP cash flow from operations of $89,456,000, capital expenditures of $21,905,000 compared to the total revenue of $589,450,000, operating income of $221,188,000, income before income taxes of $225,312,000, net income of $142,593,000 or $1.82 per diluted share, non-GAAP operating income of $235,446,000, non-GAAP net income of $152,514,000 or $1.95 per diluted share, GAAP cash flow from operations of $149,280,000, capital expenditures of $9,653,000 for the same period a year ago. The company projected total revenues for the fiscal fourth quarter ending June 30, 2015 of $187 million to $189 million and adjusted diluted earnings per share of $0.40 to $0.42 (GAAP diluted EPS of $0.28 to $0.30). Based on the fourth quarter financial guidance and third quarter financial results, the company revised its fiscal year 2015 financial guidance and now expects total revenues of $720 million to $722 million, down from the Feb. 3 guidance of $730 million to $740 million. Adjusted EPS is now seen between $1.44 and $1.46, down from the previous guidance range between $1.50 and $1.55. GAAP diluted EPS of $1.09 to $1.11. The primary reasons for this guidance revision are related to the impact of severe weather on fiscal third-quarter revenue, a delay in Medicare reimbursement for Prolaris until the first quarter of fiscal year 2016, and a delay in international reimbursement.

Myriad Genetics Inc. to Report Q3, 2015 Results on May 05, 2015

Myriad Genetics Inc. announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on May 05, 2015

Myriad Genetics Inc., Q3 2015 Earnings Call, May 05, 2015

Myriad Genetics Inc., Q3 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €31.41 EUR +0.57

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.94 USD -0.24
Alliance HealthCare Services Inc $20.06 USD -0.19
Bio-Reference Laboratories Inc $33.35 USD -0.41
Genomic Health Inc $27.24 USD +0.13
RadNet Inc $6.78 USD -0.02
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 27.6x
Price/Sales 3.4x
Price/Book 3.6x
Price/Cash Flow 25.3x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.